公开(公告)号：US10000451B2

公开(公告)日：2018-06-19

申请号：US15650902

申请日：2017-07-15

Applicant: SRI INTERNATIONAL

Inventor： Ling Jong ,  Chih-Tsung Chang ,  Jaehyeon Park

IPC: C07D403/02 ,  A61K31/404 ,  C07D209/14 ,  C07D209/12 ,  C07D405/02

CPC classification number: C07D209/14 ,  A61K31/404 ,  C07D209/08 ,  C07D209/12 ,  C07D209/30 ,  C07D403/02 ,  C07D403/06 ,  C07D405/02 ,  C07D405/06 ,  C07D471/04

Abstract: The invention provides mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) inhibitors, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant diminution of tumor cell growth, cancer or metastasis.

公开(公告)号：US20190255059A1

公开(公告)日：2019-08-22

申请号：US16334229

申请日：2017-09-29

Applicant: SRI INTERNATIONAL

Inventor： Thomas R. Webb ,  Jaehyeon Park ,  Chandraiah Lagisetti

IPC: A61K31/52 ,  A61P35/00 ,  C07D473/32

Abstract: This disclosure generally relates to dual CLK2/CDK1 inhibitors or more potent and specific CLK inhibitors to target CLK2 and CDK1 kinases in the treatment of germ-line mutations of the spliceosome leading to the development of cancers and other human disease. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20170320824A1

公开(公告)日：2017-11-09

申请号：US15650902

申请日：2017-07-15

Applicant: SRI INTERNATIONAL

Inventor： Ling Jong ,  Chih-Tsung Chang ,  Jaehyeon Park

IPC: C07D209/14 ,  C07D209/12 ,  C07D403/02 ,  C07D405/02

CPC classification number: C07D209/14 ,  A61K31/404 ,  C07D209/08 ,  C07D209/12 ,  C07D209/30 ,  C07D403/02 ,  C07D403/06 ,  C07D405/02 ,  C07D405/06 ,  C07D471/04

Abstract: The invention provides mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) inhibitors, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant diminution of tumor cell growth, cancer or metastasis.

公开(公告)号：US20240228495A1

公开(公告)日：2024-07-11

申请号：US17913824

申请日：2021-03-24

Applicant: SRI INTERNATIONAL

Inventor： Thomas R. Webb ,  Chandraiah Lagisetti ,  Diane Beylkin ,  Jaehyeon Park ,  Wei Zhou ,  Peter Madrid ,  Leyi Gong ,  Jeremiah Malerich ,  Chat Gheong Gabriel Fung ,  Raymond Ng ,  Quentin Perron ,  Vinicius Barros Ribeiro da Silva

IPC: C07D487/04 ,  A61K31/519 ,  A61K31/551 ,  A61K45/06

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/551 ,  A61K45/06

Abstract: The present disclosure is concerned with 9-hydroxy-6-(pyrrolidin-2-yl)-3, 4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione compounds for the treatment of various viral infections such as, for example, influenza virus. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US10722515B2

公开(公告)日：2020-07-28

申请号：US16334229

申请日：2017-09-29

Applicant: SRI INTERNATIONAL

Inventor： Thomas R. Webb ,  Jaehyeon Park ,  Chandraiah Lagisetti

IPC: A61K31/522 ,  A61K31/52 ,  A61P35/00 ,  C07D473/32 ,  C07D473/16 ,  A61K31/437

Abstract: The disclosure generally relates to substituted purine analogs that are dual CLK2/CDK1 inhibitors or more potent and specific CLK inhibitors to target CLK2 and CDK1 kinases. These compounds may be useful in the treatment of germ-line mutations of the spliceosome leading to the development of cancers and other human disease. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US11337981B2

公开(公告)日：2022-05-24

申请号：US16886290

申请日：2020-05-28

Applicant: SRI INTERNATIONAL

Inventor： Thomas R. Webb ,  Jaehyeon Park ,  Chandraiah Lagisetti

IPC: C07D473/16 ,  A61K31/52 ,  A61P35/00 ,  C07D473/32 ,  A61K31/437 ,  C07D487/04

Abstract: The disclosure generally relates to substituted purine analogs that are dual CLK2/CDK1 inhibitors or more potent and specific CLK inhibitors to target CLK2 and CDK1 kinases. These compounds may be useful in the treatment of germ-line mutations of the spliceosome leading to the development of cancers and other human disease. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.